Subtype
Anaplastic Astrocytoma
CI-CAN-00000439Explore in graph →
37 active trials1 approved drugs8 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000439Explore in graph →
Clinical trials
209 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (45)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00610571 | Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | completed | Phase 1 | 62 | Katy PetersOTHER | 1 | Oct 25, 2013 | clinicaltrials |
| NCT00612651 |
| PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas |
| completed |
| Phase 1 |
| 37 |
| Duke UniversityOTHER |
| 1 |
| Feb 20, 2013 |
| clinicaltrials |
| NCT00006773 | Bortezomib in Treating Patients With Recurrent Glioma | terminated | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00110032 | Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors | terminated | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00734864 | Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma | withdrawn | Phase 1 | 0 | Annick DesjardinsOTHER | 1 | Nov 21, 2012 | clinicaltrials |
| NCT00272870 | Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy | terminated | Phase 1 | 1 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Aug 29, 2012 | clinicaltrials |
| NCT00089427 | IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 24 | INSYS Therapeutics IncINDUSTRY | 1 | Jul 4, 2011 | clinicaltrials |
| NCT00024557 | Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients | completed | Phase 1 | 40 | INSYS Therapeutics IncINDUSTRY | 1 | Jun 6, 2011 | clinicaltrials |
| NCT00041587 | Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 / Phase 2 | 80 | INSYS Therapeutics IncINDUSTRY | 3 | Jun 6, 2011 | clinicaltrials |
| NCT00064779 | Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma | completed | Phase 1 | 18 | INSYS Therapeutics IncINDUSTRY | 1 | Jun 6, 2011 | clinicaltrials |
| NCT00115440 | BNCT to Treat Glioma That Has Progressed Following Radiotherapy | completed | Phase 1 / Phase 2 | 22 | Boneca CorporationINDUSTRY | 1 | Jan 28, 2009 | clinicaltrials |
Data updated 22 days agoSource updated May 23, 2014source: clinicaltrials